Lexeo Therapeutics (LXEO) Other Accumulated Expenses (2022 - 2026)

Lexeo Therapeutics has disclosed Other Accumulated Expenses across 5 years of filings, most recently posting $103000.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $103000.0, down 84.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $103000.0 (down 84.6% YoY), and the FY2025 annual result was $73000.0, down 86.61% from the prior year.
• Other Accumulated Expenses came in at $103000.0 for Q1 2026 at Lexeo Therapeutics, up from $73000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $669000.0 in Q1 2025 to a low of $73000.0 in Q4 2025.
• The 5-year median for Other Accumulated Expenses is $197500.0 (2025), against an average of $306250.0.
• Peak annual rise in Other Accumulated Expenses reached 280.11% in 2025, while the deepest fall reached 86.61% in 2025.
• Lexeo Therapeutics' Other Accumulated Expenses stood at $240000.0 in 2022, then jumped by 130.83% to $554000.0 in 2023, then slipped by 1.62% to $545000.0 in 2024, then sank by 86.61% to $73000.0 in 2025, then surged by 41.1% to $103000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $103000.0 (Q1 2026), $73000.0 (Q4 2025), and $209000.0 (Q3 2025), per Business Quant data.